307 related articles for article (PubMed ID: 33674603)
1. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma.
Schäfer D; Tomiuk S; Küster LN; Rawashdeh WA; Henze J; Tischler-Höhle G; Agorku DJ; Brauner J; Linnartz C; Lock D; Kaiser A; Herbel C; Eckardt D; Lamorte M; Lenhard D; Schüler J; Ströbel P; Missbach-Guentner J; Pinkert-Leetsch D; Alves F; Bosio A; Hardt O
Nat Commun; 2021 Mar; 12(1):1453. PubMed ID: 33674603
[TBL] [Abstract][Full Text] [Related]
2. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
Front Immunol; 2020; 11():1704. PubMed ID: 32849600
[TBL] [Abstract][Full Text] [Related]
3. The tetraspanins CD151 and Tspan8 are essential exosome components for the crosstalk between cancer initiating cells and their surrounding.
Yue S; Mu W; Erb U; Zöller M
Oncotarget; 2015 Feb; 6(4):2366-84. PubMed ID: 25544774
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract][Full Text] [Related]
5. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
[TBL] [Abstract][Full Text] [Related]
6. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
Kryza T; Khan T; Puttick S; Li C; Sokolowski KA; Tse BW; Cuda T; Lyons N; Gough M; Yin J; Parkin A; Deryugina EI; Quigley JP; Law RHP; Whisstock JC; Riddell AD; Barbour AP; Wyld DK; Thomas PA; Rose S; Snell CE; Pajic M; He Y; Hooper JD
Theranostics; 2020; 10(9):4116-4133. PubMed ID: 32226543
[No Abstract] [Full Text] [Related]
7. Engineered T cells for pancreatic cancer treatment.
Katari UL; Keirnan JM; Worth AC; Hodges SE; Leen AM; Fisher WE; Vera JF
HPB (Oxford); 2011 Sep; 13(9):643-50. PubMed ID: 21843265
[TBL] [Abstract][Full Text] [Related]
8. Tspan8 and CD151 promote metastasis by distinct mechanisms.
Yue S; Mu W; Zöller M
Eur J Cancer; 2013 Sep; 49(13):2934-48. PubMed ID: 23683890
[TBL] [Abstract][Full Text] [Related]
9. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma.
Raj D; Nikolaidi M; Garces I; Lorizio D; Castro NM; Caiafa SG; Moore K; Brown NF; Kocher HM; Duan X; Nelson BH; Lemoine NR; Marshall JF
Clin Cancer Res; 2021 Mar; 27(5):1538-1552. PubMed ID: 33479048
[TBL] [Abstract][Full Text] [Related]
10. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
[TBL] [Abstract][Full Text] [Related]
11. SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer.
Li J; Chen X; Zhu L; Lao Z; Zhou T; Zang L; Ge W; Jiang M; Xu J; Cao Y; Du S; Yu Y; Fan G; Wang H
Oncogene; 2021 Jul; 40(30):4884-4893. PubMed ID: 34163029
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target.
Pandey R; Zhou M; Islam S; Chen B; Barker NK; Langlais P; Srivastava A; Luo M; Cooke LS; Weterings E; Mahadevan D
Sci Rep; 2019 Dec; 9(1):18347. PubMed ID: 31797958
[TBL] [Abstract][Full Text] [Related]
13. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.
Bailey P; Chang DK; Forget MA; Lucas FA; Alvarez HA; Haymaker C; Chattopadhyay C; Kim SH; Ekmekcioglu S; Grimm EA; Biankin AV; Hwu P; Maitra A; Roszik J
Sci Rep; 2016 Oct; 6():35848. PubMed ID: 27762323
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
15. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
[TBL] [Abstract][Full Text] [Related]
16. CD318 is a ligand for CD6.
Enyindah-Asonye G; Li Y; Ruth JH; Spassov DS; Hebron KE; Zijlstra A; Moasser MM; Wang B; Singer NG; Cui H; Ohara RA; Rasmussen SM; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6912-E6921. PubMed ID: 28760953
[TBL] [Abstract][Full Text] [Related]
17. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
Front Immunol; 2022; 13():958960. PubMed ID: 35990619
[TBL] [Abstract][Full Text] [Related]
18. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells.
Fujiwara K; Ohuchida K; Sada M; Horioka K; Ulrich CD; Shindo K; Ohtsuka T; Takahata S; Mizumoto K; Oda Y; Tanaka M
PLoS One; 2014; 9(9):e107247. PubMed ID: 25221999
[TBL] [Abstract][Full Text] [Related]
19. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
20. T cell optimization for the treatment of pancreatic cancer.
Liu F; Saif MW
Expert Opin Biol Ther; 2017 Dec; 17(12):1493-1501. PubMed ID: 28835191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]